Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:18:18.464Z.
Calculation as of: 2026-10-06T16:18:18.464Z.
Quote observation: 2026-10-06T16:14:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4553d85706fed5bac33927ddb0c45062b9ca990621471d16f8faa1ad8920ffc8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$163.00M
EV/EBIT Ratio
N/A
TTM Avg
8.53x
3Y Avg
141.14x
5Y Avg
141.14x
Market Cap
$159.09M
EV/EBIT Ratio
N/A
TTM Avg
24.87x
3Y Avg
24.87x
5Y Avg
24.87x
Market Cap
$165.58M
EV/EBIT Ratio
14.25x
TTM Avg
19.02x
3Y Avg
19.02x
5Y Avg
327.42x
Market Cap
$155.86M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$169.85M
EV/EBIT Ratio
N/A
TTM Avg
286.64x
3Y Avg
136.18x
5Y Avg
72.17x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $162.89M | N/A | N/A | N/A | N/A |
| Quanterix Corporation (QTRX)vs › | $164.16M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $163.00M | N/A | 8.53x | 141.14x | 141.14x |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.09M | N/A | 24.87x | 24.87x | 24.87x |
| Inogen, Inc. (INGN)vs › | $158.12M | N/A | 189.93x | 95.49x | 94.46x |
| OptimizeRx Corp. (OPRX)vs › | $165.58M | 14.25x | 19.02x | 19.02x | 327.42x |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | N/A | N/A | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.85M | N/A | 286.64x | 136.18x | 72.17x |
| MediWound Ltd. (MDWD)vs › | $171.62M | N/A | 8.18x | 8.18x | 8.18x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $153.40M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
